Epitranscriptomic Profiling for Glioma Grade Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for gliomas, particularly glioblastomas, are inadequate due to the difficulty in distinguishing between grades II and III, relying on costly and time-consuming anatomopathological analyses, and lack of effective biomarkers for early detection and personalized treatment.
Innovation Solution
An in vitro method utilizing quantitative analysis of modified and unmodified nucleosides from biological samples through epitranscriptomic profiling, combined with machine learning algorithms for predicting tumor grade and presence, enabling early characterization and patient stratification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If anatomopathological analysis is used to determine tumor grade, then diagnostic accuracy is improved, but cost and time consumption increase
Solution Approach 1:
The patent replaces manual anatomopathological analysis with automated mass spectrometry-based epitranscriptomic profiling. The system uses liquid chromatography coupled with mass spectrometry (LC-MS/MS) to quantitatively analyze nucleoside modifications, substituting the mechanical and visual expertise-based process with an automated analytical instrument that provides objective, reproducible results without requiring specialist interpretation time.
Solution Approach 2:
The patent introduces epitranscriptomic profiles as an intermediary biomarker system between the tumor tissue and the diagnostic conclusion. Instead of directly analyzing tissue morphology requiring expert interpretation, the system measures nucleoside modification patterns (m6A, m5C, pseudouridine, etc.) that serve as intermediate indicators of tumor grade, enabling automated classification while preserving diagnostic accuracy.
2Measurement precision
If anatomopathological analysis is used to determine tumor grade, then diagnostic accuracy is improved, but cost increases
Solution Approach 1:
The patent replaces expensive manual expert analysis with automated mass spectrometry instrumentation. While the instrument represents a capital investment, it eliminates ongoing costs associated with specialist pathologist time and reduces variability in diagnostic accuracy. The standardized automated protocol enables high-throughput analysis at lower marginal cost per sample compared to expert anatomopathological review.
Solution Approach 2:
The patent shifts the diagnostic parameters from morphological features requiring expert visual assessment to quantitative chemical measurements of nucleoside modifications. This parameter transformation enables the use of automated analytical chemistry methods that are more cost-effective at scale while providing objective, reproducible quantitative data rather than subjective visual grading.
3Reliability
If current diagnostic methods are used, then tumor detection is possible, but early stage detection capability is insufficient
Solution Approach 1:
The patent enables preliminary detection and grading of tumors before surgical intervention or before tumors reach advanced stages. By analyzing epitranscriptomic profiles from biopsy samples or liquid biopsies, the system can identify tumor presence and grade at early stages, allowing for earlier treatment decisions and patient stratification before the disease progresses.
Solution Approach 2:
The patent uses epitranscriptomic biomarkers as intermediaries that can be detected in various sample types including liquid biopsies, enabling non-invasive or minimally invasive early detection. These molecular signatures serve as early warning indicators that precede anatomical changes detectable by conventional imaging or gross pathological examination.
4Loss of information
If histological classification is used, then tumor characterization is achieved, but reproducibility decreases
Solution Approach 1:
The patent replaces subjective visual histological classification with objective automated mass spectrometry measurement. The system quantitatively measures nucleoside modification levels (such as m6A, m5C, pseudouridine) using standardized protocols and computational analysis, eliminating inter-observer variability between pathologists while preserving comprehensive tumor characterization information.
Solution Approach 2:
The patent transforms subjective morphological parameters into objective quantitative chemical parameters. Instead of relying on visual assessment of tissue architecture and cellular features that vary between observers, the system measures precise quantitative ratios of modified to unmodified nucleosides, providing reproducible numerical data that can be consistently interpreted across different laboratories and time points.
Data Source
AI summary
An in vitro method is disclosed for characterizing a tumour, based on the quantitative analysis of modified and unmodified nucleosides from total cellular RNA, from extracellular RNA and/or from isolated nucleosides, extracted from a biological sample. More particularly, the invention relates to a method for predicting the grade of a glial tumour. More particularly, the invention also relates to a method for detecting a tumour. The present invention therefore lies in the fields of cancerology and molecular biology, more particularly applied to medical diagnosis.